Related references
Note: Only part of the references are listed.Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study
Alessandra Raimondi et al.
EUROPEAN JOURNAL OF CANCER (2020)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Filippo Pietrantonio et al.
JAMA ONCOLOGY (2019)
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Federica Morano et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
F. Marmorino et al.
ANNALS OF ONCOLOGY (2019)
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110)
Dominik Paul Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Herbert Hurwitz et al.
ONCOLOGIST (2019)
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C. Cremolini et al.
ANNALS OF ONCOLOGY (2018)
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
Chiara Cremolini et al.
BRITISH JOURNAL OF CANCER (2018)
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
Fotios Loupakis et al.
BRITISH JOURNAL OF CANCER (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Chiara Cremolini et al.
EUROPEAN JOURNAL OF CANCER (2017)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C. Cremolini et al.
ANNALS OF ONCOLOGY (2017)
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
K. K. H. Goey et al.
ANNALS OF ONCOLOGY (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
E. Missiaglia et al.
ANNALS OF ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments
Peter C. Austin
STATISTICS IN MEDICINE (2014)
Recent Developments in the Econometrics of Program Evaluation
Guido W. Imbens et al.
JOURNAL OF ECONOMIC LITERATURE (2009)
Covariate balance in simple, stratified and clustered comparative studies
Ben B. Hansen et al.
STATISTICAL SCIENCE (2008)
Share Paper
